RESUMO
BACKGROUND@#Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited. @*METHODS@#Bone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluated in vivo using immunohistochemical analysis. @*RESULTS@#EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4 ) induced mouse liver fibrosis model. @*CONCLUSION@#EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.
RESUMO
BACKGROUND@#Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited. @*METHODS@#Bone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluated in vivo using immunohistochemical analysis. @*RESULTS@#EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4 ) induced mouse liver fibrosis model. @*CONCLUSION@#EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.
RESUMO
BACKGROUND: Mesenchymal stem cell-based therapy is pursued aggressively with promising preclinical studies and higher future prospect in the treatment of nonhealing wounds. OBJECTIVE: To review the strategies for improving the efficacy of mesenchymal stem cells in the treatment of nonhealing wounds, which are expected to provide theoretical basis for clinical treatment of nonhealing wounds. METHODS: Wanfang, CNKI, PubMed and Web of Science were searched for articles about the application of mesenchymal stem cells in nonhealing wounds from March 2002 to March 2020. The key words were “mesenchymal stem cells, nonhealing wounds (nonhealing chronic wounds), wound repair, tissue regeneration” in Chinese and “mesenchymal stem cells, nonhealing chronic wound, wound repair, tissue regeneration” in English. After excluding outdated and repetitive viewpoints, the retrieved literature was sorted out and a total of 64 articles were included for analysis. RESULTS AND CONCLUSION: (1) The formation mechanism of nonhealing wounds was summarized. (2) The molecular mechanisms of mesenchymal stem cells in the treatment of nonhealing wounds were summarized, such as direct differentiation, paracrine, immunomodulatory, mobilization resident stem cells to participate in wound repair. (3) This paper summarized the improvement of the efficacy of mesenchymal stem cells in the treatment of nonhealing wounds, such as gene modification and pretreatment. (4) This study can provide a theoretical basis for improving the efficacy of mesenchymal stem cells in the treatment of nonhealing wounds.